2 min read
2 min read
February 2021
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in February 2021.
New FDA Guidance Documents:
Development of Monoclonal Antibody Products Targeting SARSCoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency Guidance for Industry (22 Feb 2021)
Download FDA Guidance
Emergency Use Authorization for Vaccines to Prevent COVID-19 Guidance for Industry (22 Feb 2021)
Download FDA Guidance
Investigational COVID-19 Convalescent Plasma Guidance for Industry (11 Feb 2021)
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine (27Feb2021)
Read FDA News Release
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A (26 Feb2021)
Read FDA News Release
Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine (25Feb2021)
Read FDA News Release
Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants (22Feb2021)
Read FDA News Release
FDA Approves First in the World, First-of-Its-Kind Implant for the Treatment of Rare Bone Disease as a Humanitarian Use Device (17Feb2021)
Read FDA News Release
EMA releases guidance for COVID variant vaccine development (25Feb2021)
Read Article on RAPS.org
England and Canada diverge from US on cancer drug decisions (25Feb2021)
Read Article on RAPS.org
EMA plots earlier engagement with patient groups (19Feb2021)
Read Article on RAPS.org
Navigating the maze of electronic submissions at EMA (12Feb2021)
Read Article on RAPS.org
EU regulators expand use of remote source data verification in clinical trials (08Feb2021)
Read Article on RAPS.org
OCE year 4: Progress despite a pandemic (08Feb2021)
EMA, MHRA update on COVID vaccine pharmacovigilance (08Feb2021)
Read Article on RAPS.org
FDA outlines process for communicating record requests findings (02Feb2021)
Read Article on RAPS.org
New toolbox available for EMA's PRIME designees (02Feb2021)
Read Article on RAPS.org
CBER lays out scaled-down guidance agenda for 2021 (02Feb2021)
Read Article on RAPS.org
Inspections: GAO calls on FDA to plan for backlog, review alternatives (01Feb2021)
-
Read our latest news: Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical
-
Register now for an upcoming webinar: How to Better Plan Your Virtual Clinical Trial
-
Learn how Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020
- Download our COVID-19 Guide on Strategies For Success During the COVID-19 Era
- Read our infographic to Understand FDA Expedited Pathways for Accelerating Time-to-Market for Products Treating Serious Conditions or Unmet Medical Needs
- Download the Infographic explaining the Types of FDA Meetings with CDER and CBER